Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Antibody Discovery Services
Overview
Target Analysis & Immunization
Antibody Discovery & Characterization
Developability Profiling
Optimization & Engineering
Preclinical Services
Protein Production
Overview
 
Online Store

Explore now

See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
AI Technology
LENSai Applications
The LENSai Difference
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Resources
Antibody Discovery Resources
AI Technology Resources
IPA Collective
Resource Spotlight
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Company
Overview
Leadership
Investor Relations
Careers
Locations
Contact Us
News
News & Press Releases
Events
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

In the News

Contact Us

IPA News
January 17th, 2025
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
AUSTIN, Texas – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to transform therapeutic development. By combining advanced artificial...
November 13th, 2024
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
Innovative Antibodies Show Promise for Antibody-Drug Conjugate (ADC) Development, Paving the Way for Transformative Cancer Treatments VICTORIA, BRITISH COLUMBIA (CANADA), November 13, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or...
November 4th, 2024
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
VICTORIA, BRITISH COLUMBIA (CANADA), November 4, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA),an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday,...
October 28th, 2024
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
Rabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction VICTORIA, BRITISH COLUMBIA (CANADA), October 28, 2024 – ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an...
October 21st, 2024
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
VICTORIA, BRITISH COLUMBIA (CANADA), October 21, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation...
October 10th, 2024
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
University of Washington’s Baker Lab and Google DeepMind Redefine Protein Science, Paving the Way for AI-Driven Biotherapeutics VICTORIA, BRITISH COLUMBIA (CANADA), October 10, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”)...
October 2nd, 2024
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
Talem Therapeutics' Antibody Asset to be Evaluated for Bispecific Development Against Solid Tumors VICTORIA, BRITISH COLUMBIA (CANADA), ZHUAI, (CHINA), October 2, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an...
June 27th, 2024
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
VICTORIA, BRITISH COLUMBIA (CANADA), June 27, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce the appointment of Kristin Taylor as Chief...
June 25th, 2024
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
VICTORIA, BRITISH COLUMBIA (CANADA), June 25, 2024 – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating...
June 12th, 2024
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
VICTORIA, British Columbia, June 12, 2024 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand,...
June 10th, 2024
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
-BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models. ...
June 4th, 2024
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
Dirk Van Hyfte MD, PhD, Head of Technology, IPA, to present live demonstration at the InterSystems Global Summit 2024 June 9-12, 2024 - National Harbor, Maryland VICTORIA, BRITISH COLUMBIA (CANADA), June 04, 2024 – IPA (IMMUNOPRECISE...
March 28th, 2024
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
VICTORIA, BRITISH COLUMBIA (CANADA), March 28, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical...
March 20th, 2024
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
Significant throughput of LSA to advance IPA’s diversity- and data-driven drug development and to enrich LENSai™. VICTORIA, BRITISH COLUMBIA (CANADA), March 20, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), ...
March 7th, 2024
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand, to present findings live next week at the HIMSS24 conference in Orlando, Florida VICTORIA, BRITISH COLUMBIA (CANADA), March 7, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.)...
November 27th, 2023
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
VICTORIA, British Columbia, November 27, 2023 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is pleased to announce important Board of Director...
November 13th, 2023
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary,...
July 14th, 2023
ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
VICTORIA, British Columbia, July 14 - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology, is delighted to extend an invitation to investors and other interested parties to...
June 13th, 2023
IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
VICTORIA, British Columbia, June 13, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited to announce a new use case for the Information Integration...
June 6th, 2023
IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market
VICTORIA, British Columbia, June 6, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”) today introduced a transformative AI-driven rapid therapeutic screening platform, the result of a collaboration between IPA Canada and...
May 30th, 2023
IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
VICTORIA, British Columbia May 30, 2023 – ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has...
March 30th, 2023
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
Agreement Focuses on in silico and de novo Discovery and Development of Antibodies Against Tumor Microenvironment Targets. Program will Leverage BioStrand’s (a Talem Affiliate) LENSᵃⁱ® Integrated Intelligence Technology®, Built Upon the...
March 27th, 2023
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
Company Received Official Notice from the European Patent Office (EPO) for the Decision to Grant its Patent Application on April 5th, 2023. The Patent was Initially Filed February 7th, 2020. Patent Application Covers a Method to Efficiently...
March 16th, 2023
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023
IPA’s Project revenue increased by 16.7% compared to the prior year, driven by the growth of the company's proprietary B cell Select® platform and protein manufacturing services. Talem Therapeutics has announced a collaboration with Libera Bio to...
March 15th, 2023
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
The program will leverage BioStrand’s LENSai® Full Suite of Integrated Intelligence Technology® with Libera Bio’s Multifunctional Polymeric Nanocapsules (MPN Technology®) The Alliance has Stipulated a Minimum of Upfront and Downstream Milestone...